1. Advances in Cystic Fibrosis: Perspectives from Phoenix 2015

3. Advances in Cystic Fibrosis Perspectives from Phoenix 2015

4. Possible Interaction of Azithromycin + Tobramycin Background/Methods

5. Possible Interaction of Azithromycin + Tobramycin Clinical Results

6. Possible Interaction of Azithromycin + Tobramycin In Vitro Results

8. AeroVanc Phase 2 Trial

10. Advances in Cystic Fibrosis Perspectives from Phoenix 2015

11. PROGRESS Trial

12. PROGRESS Trial Results

13. PROGRESS Trial Conclusions

14. Pooled Analysis of TRAFFIC/TRANSPORT Design

15. Pooled Analysis of TRAFFIC/TRANSPORT Efficacy

16. Long-Term Ivacaftor in Severe CF Results

17. Advances in Cystic Fibrosis Perspectives from Phoenix 2015

18. Perceptions of Depression Screening

19. Dissemination of the Buffalo Approach to Depression Screening Background

20. Development of a Comprehensive Transition Program

21. “Dallas Dashboard” for Transition

22. Advances in Cystic Fibrosis Perspectives from Phoenix 2015

23. ENVISION Linear Growth With Ivacaftor

24. CRC Screening in CF

25. CRC Screening in CF Results

26. STOP Study

27. Advances in Cystic Fibrosis Perspectives from Phoenix 2015

28. The GOAL-E2 Study Design

29. The GOAL-E2 Study Changes from Baseline to 1 Month (n = 45)

30. The GOAL-E2 Study Implications

31. Abbreviations

32. Abbreviations (cont)

33. References

34. References (cont)

35. References (cont)